Liraglutide

Liraglutide is a synthetic version of the human hormone glucagon-like peptide-1 (GLP-1). It was developed as a once-daily injectable treatment for type 2 diabetes, and later approved for chronic weight management in adults Liraglutide and obesity: a review of the data so far+1. In research, liraglutide helps control blood sugar by stimulating insulin release only when glucose is high, slowing stomach emptying, and reducing appetite. It is also studied for cardiovascular risk reduction and in adolescents with obesity Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026)+2.

Liraglutide binds to the GLP-1 receptor, the same target as the body's own GLP-1 hormone. This sets off a chain of events:

• In the pancreas, it boosts insulin secretion only when blood sugar is high, while lowering glucagon (a hormone that raises blood sugar).
• In the stomach, it slows the rate food moves into the intestine, helping you feel full longer.
• In the brain, it signals satiety, cutting appetite Liraglutide and obesity: a review of the data so far+1.

Because the insulin release is glucose-dependent, liraglutide alone rarely causes dangerously low blood sugar Liraglutide and obesity: a review of the data so far. Its weight-loss effect comes mainly from eating fewer calories, not burning more energy Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation+1.

Weight loss

In adults, clinical trials and real‑world data show liraglutide (3.0 mg daily) leads to average weight loss of 5–10% of body weight over 26–52 weeks Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026)+2. A network meta‑analysis ranked it effective but less potent than semaglutide or tirzepatide Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.

Glycemic control

For type 2 diabetes, liraglutide (1.2–1.8 mg daily) reduces HbA1c by about 1%, with a low risk of hypoglycemia when used alone Evaluating the bioequivalence and safety of liraglutide injection versus Victoza® in healthy Chinese subjects: a randomized, open, two-cycle, self-crossover phase I clinical trial+1.

Cardiovascular outcomes

A re‑analysis of the LEADER trial estimated a modest reduction in cardiovascular events (11.8% with liraglutide vs. 13.3% with placebo) over 3.5 years Accounting for non-adherence: A re-analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results trial.

Body composition

Liraglutide preferentially reduces fat mass, but some lean body mass loss (about 1.5 kg) has been reported. Muscle loss can be mitigated with adequate protein and resistance training Comparative Effects of Antidiabetic Drugs on Body Composition: A Systematic Review and Network Meta-Analysis+1.

Adolescent obesity

In youth, liraglutide produced about a 4.3% BMI reduction over 56 weeks, less than semaglutide but better than lifestyle alone GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists+1.

Standard dosing for obesity in adults starts at 0.6 mg daily and increases each week by 0.6 mg until reaching 3.0 mg, to minimize nausea and other stomach side effects Liraglutide and obesity: a review of the data so far+1. Diabetes protocols often stop at 1.8 mg. Studies show weight loss continues to improve over 6–12 months, so research protocols often continue for at least 26 weeks Liraglutide 3.0 mg (Saxenda©) for Weight Loss and Remission of Pre-Diabetes. Real-World Clinical Evaluation of Effectiveness among Patients Awaiting Bariatric Surgery+1.

The dose is fixed, not based on body weight. For those who cannot tolerate the full dose, staying at a lower effective dose (e.g., 1.8–2.4 mg) is common Liraglutide and obesity: a review of the data so far. The visual timeline above shows the typical weekly escalation pattern used in research.

Liraglutide is normally supplied as a pre‑filled multi‑dose injection pen at 6 mg/mL, so standard use does not require reconstitution Liraglutide and obesity: a review of the data so far. If a lyophilized powder is available for research, it is typically mixed with bacteriostatic water using sterile technique. The powder and reconstituted solution should be stored in the refrigerator; once mixed, it is best used within 28–30 days. Avoid shaking to prevent foaming.

An interactive reconstitution calculator below can help you determine the correct volumes for your target dose and concentration.

Liraglutide can increase the risk of low blood sugar when combined with insulin or sulfonylureas, so these medications may need dose adjustments Liraglutide and obesity: a review of the data so far. Because it slows stomach emptying, liraglutide may delay the absorption of oral drugs; if you take a time‑sensitive medication (like certain contraceptives or thyroid hormone), it may be best to take it at a different time of day Liraglutide and obesity: a review of the data so far. Combining liraglutide with another GLP-1 agonist is not recommended.

The table above summarizes the most clinically relevant interactions, including those with anesthesia (increased aspiration risk), diuretics/NSAIDs (dehydration), and oral contraceptives (possible reduced efficacy).

Liraglutide is not typically cycled in the sense of planned on/off periods. Research supports continuous use for sustained benefits; weight regain often occurs after stopping Liraglutide and obesity: a review of the data so far. Breaks may be taken if side effects become intolerable or a plateau occurs, but there is no evidence that cycling improves long‑term weight‐loss outcomes. Repeated stops and starts can lead to repeated nausea during re‑titration.

For some, a “conservative tolerance‑first” approach is used: start at a low dose and increase more slowly than the standard schedule, which can reduce GI side effects Liraglutide and obesity: a review of the data so far. If you stop, re‑start at the lowest dose and escalate again.

Liraglutide is sometimes stacked with other investigational peptides for body recomposition, but human data on such combinations are very limited. Because liraglutide itself reduces appetite and can lower lean body mass, stacking it with growth hormone secretagogues (e.g., CJC-1295, ipamorelin) may help preserve muscle during a cut, but this remains theoretical Comparative Effects of Antidiabetic Drugs on Body Composition: A Systematic Review and Network Meta-Analysis+1. Combining liraglutide with other appetite‑suppressing agents can worsen nausea and dehydration.

It is not recommended to combine liraglutide with another GLP‑1 receptor agonist, as this only increases side effects without additional benefit Liraglutide and obesity: a review of the data so far.

Liraglutide is FDA‑approved in the United States for type 2 diabetes (sold as Victoza) and for chronic weight management (sold as Saxenda) Human medicines European public assessment report (EPAR): Victoza, liraglutide, Diabetes Mellitus, Type 2, Date of authorisation: 30/06/2009, Revision: 19, Status: Authorised+2. It is also authorized in the European Union and many other countries. It is a prescription medication and not a controlled substance.

For athletes, liraglutide is not currently listed as prohibited by the World Anti‑Doping Agency (WADA), but you should always check with your sport’s governing body before use. Counterfeit liraglutide pens have been reported, so sourcing from legitimate pharmacies is important Falsified Ozempic (semaglutide) and Saxenda (liraglutide).

The most common side effects of liraglutide are nausea, vomiting, diarrhea, and constipation, especially during the first few weeks of treatment or after dose increases Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians+1. These usually improve with slower dose escalation and smaller meals.

Rare but serious adverse events can include pancreatitis, gallbladder disease, and allergic reactions Cohort Study: Risk of Gallstones and Biliary Complications With Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes+4. Because liraglutide slows stomach emptying, there is a risk of regurgitation and aspiration during anesthesia; it is typically held before elective surgery In brief: New FDA warning of pulmonary aspiration with GLP-1 receptor agonists. Kidney injury has been reported in the context of severe dehydration from vomiting GLP-1 Agonists-Associated Kidney Toxicities.

Post‑marketing safety monitoring has noted a possible association with depressed mood and suicidal thoughts, but a causal link has not been established and clinical trials did not show an increase in suicides Association Between Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review+1.